Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Neurobiol ; 59(6): 3873-3887, 2022 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-35426574

RESUMO

Hydroxychloroquine (HCQ) is an anti-malarial drug but also widely used to treat autoimmune diseases like arthritis and lupus. Although there have been multiple reports of the adverse effect of prolonged HCQ usage on the outer retina, leading to bull's-eye maculopathy, the effect of HCQ toxicity on the inner retina as well as on overall visual functions has not been explored in detail. Furthermore, lack of an established animal model of HCQ toxicity hinders our understanding of the underlying molecular mechanisms. Here, using a small clinical study, we confirmed the effect of HCQ toxicity on the inner retina, in particular the reduction in central inner retinal thickness, and established a mouse model of chronic HCQ toxicity that recapitulates the effects observed in human retina. Using the mouse model, we demonstrated that chronic HCQ toxicity results in loss of inner retinal neurons and retinal ganglion cells (RGC) and compromises visual functions. We further established that HCQ treatment prevents autophagosome-lysosome fusion and alters the sphingolipid homeostasis in mouse retina. Our results affirm the notion that HCQ treatment causes early damage to the inner retina and affects visual functions before leading to characteristic toxicity in the macular region of the outer retina, 'bull's-eye maculopathy.' We also provide insights into the underlying molecular mechanisms of HCQ retinal toxicity that may involve autophagy-lysosomal defects and alterations in sphingolipid metabolism.


Assuntos
Antirreumáticos , Degeneração Macular , Doenças Retinianas , Animais , Antirreumáticos/efeitos adversos , Autofagossomos , Hidroxicloroquina/efeitos adversos , Lisossomos , Camundongos , Retina , Doenças Retinianas/induzido quimicamente , Doenças Retinianas/tratamento farmacológico , Esfingolipídeos , Tomografia de Coerência Óptica/métodos
2.
Mol Neurobiol ; 58(11): 5564-5580, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34365584

RESUMO

Traumatic brain injury (TBI) causes neuroinflammation and neurodegeneration leading to various pathological complications such as motor and sensory (visual) deficits, cognitive impairment, and depression. N-3 polyunsaturated fatty acid (n-3 PUFA) containing lipids are known to be anti-inflammatory, whereas the sphingolipid, ceramide (Cer), is an inducer of neuroinflammation and degeneration. Using Fat1+-transgenic mice that contain elevated levels of systemic n-3 PUFA, we tested whether they are resistant to mild TBI-mediated sensory-motor and emotional deficits by subjecting Fat1-transgenic mice and their WT littermates to focal cranial air blast (50 psi) or sham blast (0 psi, control). We observed that visual function in WT mice was reduced significantly following TBI but not in Fat1+-blast animals. We also found Fat1+-blast mice were resistant to the decline in motor functions, depression, and fear-producing effects of blast, as well as the reduction in the area of oculomotor nucleus and increase in activated microglia in the optic tract in brain sections seen following blast in WT mice. Lipid and gene expression analyses confirmed an elevated level of the n-3 PUFA eicosapentaenoic acid (EPA) in the plasma and brain, blocking of TBI-mediated increase of Cer in the brain, and decrease in TBI-mediated induction of Cer biosynthetic and inflammatory gene expression in the brain of the Fat1+ mice. Our results demonstrate that suppression of ceramide biosynthesis and inflammatory factors in Fat1+-transgenic mice is associated with significant protection against the visual, motor, and emotional deficits caused by mild TBI. This study suggests that n-3 PUFA (especially, EPA) has a promising therapeutic role in preventing neurodegeneration after TBI.


Assuntos
Sintomas Afetivos/prevenção & controle , Concussão Encefálica/sangue , Caderinas/fisiologia , Ácidos Graxos Ômega-3/sangue , Traumatismos Cranianos Fechados/sangue , Transtornos dos Movimentos/prevenção & controle , Transtornos da Visão/prevenção & controle , Sintomas Afetivos/sangue , Sintomas Afetivos/etiologia , Animais , Química Encefálica , Concussão Encefálica/complicações , Concussão Encefálica/psicologia , Caderinas/genética , Ceramidas/biossíntese , Depressão/sangue , Depressão/etiologia , Depressão/prevenção & controle , Resistência à Doença , Ácidos Graxos Ômega-3/fisiologia , Medo , Feminino , Traumatismos Cranianos Fechados/complicações , Traumatismos Cranianos Fechados/psicologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Transtornos dos Movimentos/sangue , Transtornos dos Movimentos/etiologia , Doenças Neuroinflamatórias , Teste de Campo Aberto , Estresse Oxidativo , Proteínas Recombinantes/metabolismo , Esfingolipídeos/análise , Esfingomielina Fosfodiesterase/análise , Transtornos da Visão/sangue , Transtornos da Visão/etiologia
3.
Sci Rep ; 9(1): 7771, 2019 05 23.
Artigo em Inglês | MEDLINE | ID: mdl-31123291

RESUMO

Mammalian Sphingosine kinase 2 is the primary enzyme responsible for phosphorylating FTY720 to its active form, FTY720-P. Systemic FTY720 treatment confers significant protection to murine retinas from light- and disease-mediated photoreceptor cell death. It is not clear whether FTY720-P, FTY720, or both are responsible for this photoreceptor protection. We investigated Sphingosine kinase 2 knockout (Sphk2 KO) mouse retinas, tested their sensitivity to light, and measured what degree of protection from light-induced damage they receive from systemic FTY720 treatment. Sphk2 KO retinas were found to be similar to their wild-type counterparts in sensitivity to light damage. Additionally, FTY720 treatment protected Sphk2 KO retinas from light-induced damage despite significant retardation of FTY720 phosphorylation in Sphk2 KO mice. We conclude that FTY720 serves an active role in preventing photoreceptor cell death. Furthermore, we conclude that the phosphorylation of FTY720 is not necessary to provide this protective effect.


Assuntos
Cloridrato de Fingolimode/farmacologia , Luz , Fosfotransferases (Aceptor do Grupo Álcool)/metabolismo , Retina/metabolismo , Moduladores do Receptor de Esfingosina 1 Fosfato/farmacologia , Animais , Camundongos , Camundongos Knockout , Fosforilação/efeitos dos fármacos , Fosfotransferases (Aceptor do Grupo Álcool)/genética , Retina/efeitos dos fármacos , Retina/lesões
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...